National Cancer Institute; Notice of Meeting, 56846-56847 [2023-17914]
Download as PDF
<![CDATA[
56846
Federal Register / Vol. 88, No. 160 / Monday, August 21, 2023 / Notices
Development, National Institute of Health,
6710B Rockledge Drive, Rm 2121B, Bethesda,
MD 20817, 301–451–4989, crobbins@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS.)
Dated: August 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–17887 Filed 8–18–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meeting
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Special Emphasis
Panel; Multicenter Clinical Trials; Leveraging
Network (U01 Clinical Trial Optional).
Date: September 21, 2023.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child
and Human Development, 6710B Rockledge
Drive, Room 2137B, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Vera A. Cherkasova, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Eunice Kennedy Shriver National
Institute of Child Health and Human
Development, National Institutes of Health,
6710B Rockledge Drive, Room 2137B,
Bethesda, MD 20892, (240) 478–4580,
vera.cherkasova@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.865, Research for Mothers
and Children, National Institutes of Health,
HHS)
VerDate Sep<11>2014
18:17 Aug 18, 2023
Jkt 259001
Dated: August 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–17888 Filed 8–18–23; 8:45 am]
National Cancer Institute; Notice of
Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; HEAL Initiative: Biomarker
review meeting.
Date: September 27, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Abhignya Subedi, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NIH/NINDS, NSC, 6001 Executive Blvd.,
Rockville, MD 20852, 301–496–9223,
abhi.subedi@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS.)
Dated: August 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–17886 Filed 8–18–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual
meeting and is open to the public as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting
should notify the Contact Person listed
below in advance of the meeting. The
meeting can be accessed from the NIH
Videocast at the following link: https://
videocast.nih.gov/.
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended for the review, discussion,
and evaluation of intramural programs
and projects conducted by the National
Cancer Institute, including
consideration of research scientist
qualifications and the overall
competence of those investigators to
conduct research, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy. In addition, the grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Cancer
Advisory Board.
Date: September 6, 2023.
Open: 1:00 p.m. to 4:00 p.m.
Agenda: Director’s and Program reports
and presentations; business of the Board.
Closed: 4:15 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Closed: 5:00 p.m. to 6:00 p.m.
Agenda: Review of intramural leadership
of clinical and basic research efforts and the
discussion of other related confidential
personnel issues.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
E:\FR\FM\21AUN1.SGM
21AUN1
Federal Register / Vol. 88, No. 160 / Monday, August 21, 2023 / Notices
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, where an agenda,
instructions for accessing the virtual NCAB
meetings, and any additional information for
the meetings will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 16, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–17914 Filed 8–18–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
This will be a hybrid meeting held inperson and virtually and will be open to
the public, as indicated below, with
attendance limited to space available.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance such as sign
language interpretation or other
reasonable accommodations, should
notify Dr. Gillian Acca via email at
gillian.acca@nih.gov five days in
advance of the meeting. The open
session of the meeting can be accessed
from the NIH Videocast at the following
link: https://videocast.nih.gov/.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
18:17 Aug 18, 2023
Jkt 259001
56847
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Advisory
Council on Drug Abuse.
Date: September 12, 2023.
Closed: 10:30 a.m. to 11:45 a.m.
Agenda: To review and evaluate grant
applications.
Open: 12:45 p.m. to 5:00 p.m.
Agenda: Presentations and other business
of the Council.
Place: Neuroscience Center, Conference
Room 1155/1145, National Institutes of
Health, 6001 Executive Boulevard, Rockville,
MD 20852 (Hybrid Meeting).
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North,
RM 09D08, 11601 Landsdown Street,
Bethesda, MD 20852, 301–443–6480, sweiss@
nida.nih.gov.
Contact Person: Gillian Acca, Ph.D., Health
Science Policy Analyst, Division of
Extramural Research, Office of Extramural
Policy, National Institute on Drug Abuse,
NIH, Three White Flint North, RM 09C70,
11601 Landsdown Street, Bethesda, MD
20852, 301–827–5863, gillian.acca@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to Dr. Gillian Acca via email
at gillian.acca@nih.gov. The statement
should include the name, address, telephone
number and when applicable, the business or
professional affiliation of the interested
person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meetings
Dated: August 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–17889 Filed 8–18–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Initial Review
Group Pediatrics Study Section.
Date: October 12, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6710B
Rockledge Drive, Room 2140 Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Joanna Kubler-Kielb,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, National Institutes of
Health, 6710B Rockledge Drive, Room 2140,
Bethesda, MD 20892, (301) 435–6916 kielbj@
mail.nih.gov.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Initial Review
Group Health, Behavior, and Context Study
Section.
Date: October 16, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6710B
Rockledge Drive, Room 2137C Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Kimberly L. Houston,
M.D., Scientific Review Officer, Scientific
Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, National Institutes of
Health, 6710B Rockledge Drive, Room 2137C,
Bethesda, MD 20892, (301) 827–4902,
kimberly.houston@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.865, Research for Mothers
and Children, National Institutes of Health,
HHS)
E:\FR\FM\21AUN1.SGM
21AUN1
]]>Agencies
[Federal Register Volume 88, Number 160 (Monday, August 21, 2023)]
[Notices]
[Pages 56846-56847]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-17914]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board.
The meeting will be held as a virtual meeting and is open to the
public as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting should notify the Contact Person listed below in
advance of the meeting. The meeting can be accessed from the NIH
Videocast at the following link: https://videocast.nih.gov/.
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended for the
review, discussion, and evaluation of intramural programs and projects
conducted by the National Cancer Institute, including consideration of
research scientist qualifications and the overall competence of those
investigators to conduct research, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy. In
addition, the grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: September 6, 2023.
Open: 1:00 p.m. to 4:00 p.m.
Agenda: Director's and Program reports and presentations;
business of the Board.
Closed: 4:15 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Closed: 5:00 p.m. to 6:00 p.m.
Agenda: Review of intramural leadership of clinical and basic
research efforts and the discussion of other related confidential
personnel issues.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444,
[[Page 56847]]
Bethesda, MD 20892, 240-276-6340, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm, where an agenda, instructions for accessing the
virtual NCAB meetings, and any additional information for the
meetings will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: August 16, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-17914 Filed 8-18-23; 8:45 am]
BILLING CODE 4140-01-P
